Welcome to The Dose, a blog about the business of health care. As your host, J.K. Wall, I'll be writing about the most interesting new developments I see at hospitals, doctors, insurers, employers, patients, drugmakers, device companies and medical researchers around Indianapolis and around the country.
In the first post on my new blog, The Dose, I explain why the recently released Medicare charge data are meaningless for everyone but uninsured patients.
Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
Indiana’s life sciences sector is mostly composed of legacy companies.
The future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source: smartphone apps.
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.
Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
Infuse Accelerator hopes to make early-stage investments in 12 to 15 companies a year.
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
Record sales for seeds and new crop protection products helped boost revenue 14 percent at Indianapolis-based Dow AgroSciences LLC in its new fiscal year.
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
The Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity the school has never seen before.
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
Fortunately, a Lilly takeover looks less likely today than it has in a long time—for both obvious and more subtle reasons.
The city of Indianapolis is poised to pay Citizens Energy Group $6.5 million to buy a key parcel of real estate it’s targeting as the centerpiece of its ambitious 16 Tech project.
The new investment will bring the plant’s total price tag to $320 million as the pharmaceutical giant seeks to increase production of insulin and related products.
The materials-testing business with nearly 300 employees has been acquired by Element Materials Technology. Sherry had been owned by a group of well-connected central Indiana businessmen.
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
